Head and Neck Cancer - Pipeline Review, H1 2015


Naperville, IL -- (SBWIRE) -- 03/04/2015 -- Reportstack, provider of premium market research reports announces the addition of Head And Neck Cancer - Pipeline Review, H1 2015 market report to its offering

Head And Neck Cancer - Pipeline Review, H1 2015


Head And Neck Cancer - Pipeline Review, H1 2015, provides an overview of the Head And Neck Cancers therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Head And Neck Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head And Neck Cancer and special features on late-stage and discontinued projects.

report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- The report provides a snapshot of the global therapeutic landscape of Head And Neck Cancer

- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in the therapeutics development for Head And Neck Cancer and enlists all their major and minor projects

- The report summarizes all the dormant and discontinued pipeline projects

- A review of the Head And Neck Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- A detailed assessment of monotherapy and combination therapy pipeline projects

- Coverage of the Head And Neck Cancer pipeline on the basis of target, MoA, route of administration and molecule type

- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Develop strategic initiatives by understanding the focus areas of leading companies

- Identify and understand important and diverse types of therapeutics under development for Head And Neck Cancer

- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

- Devise corrective measures for pipeline projects by understanding Head And Neck Cancer pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned

3M Drug Delivery Systems
AB Science
Acceleron Pharma, Inc.
Advaxis, Inc.
Ambrx, Inc.
Amgen Inc.
ArQule, Inc.
Ascenta Therapeutics, Inc.
Astellas Pharma Inc.
AstraZeneca PLC
AVEO Pharmaceuticals, Inc.
Bayer AG
Bexion Pharmaceuticals, LLC.
Bio-Path Holdings, Inc.
BioDiem Ltd
Bionomics Limited
Biotest AG
Boehringer Ingelheim GmbH
Boston Biomedical, Inc.
Bristol-Myers Squibb Company
CEL-SCI Corporation
Celgene Corporation
Cellceutix Corporation
Celldex Therapeutics, Inc.
Celltrion, Inc.
Centrose Llc
CTI BioPharma Corp.
Cyclacel Pharmaceuticals, Inc.
CytomX Therapeutics, Inc.
Daewoong Pharmaceutical Co., Ltd.
Daiichi Sankyo Company, Limited
EcoBiotics Limited
Eisai Co., Ltd.
Eli Lilly and Company
EntreChem, S.L.
Etubics Corporation
F. Hoffmann-La Roche Ltd.
Genelux Corporation
Genentech, Inc.
Genexine, Inc.
Genmab A/S
GlaxoSmithKline plc
Gliknik, Inc.
Glycotope GmbH
Green Cross Corporation
ImmunoGen, Inc.
Immunomedics, Inc.
Immunovative Therapies, Ltd.
Incuron, LLC
Incyte Corporation
Innate Pharma SA
Inovio Pharmaceuticals, Inc.
InteRNA Technologies B.V.
Jiangsu Kanion Pharmaceutical Co., Ltd.
Karyopharm Therapeutics, Inc.
Laboratoires Pierre Fabre SA
Lytix Biopharma AS
Mabion SA
MacroGenics, Inc.
Marsala Biotech Inc.
MedImmune, LLC
Merck & Co., Inc.
Merck KGaA
Merrimack Pharmaceuticals, Inc.
Mirati Therapeutics Inc.
Mission Therapeutics Ltd
Molplex Ltd.
Multimmune GmbH
Natco Pharma Limited
Novartis AG
Omnitura Therapeutics Inc.
Oncobiologics, Inc.
Oncolys BioPharma Inc.
Oncolytics Biotech Inc.
Onconova Therapeutics, Inc.
OncoSec Medical Inc.
Oncovir, Inc.
Ono Pharmaceutical Co., Ltd.
Otsuka Holdings Co., Ltd.
Panacea Biotec Limited
PCI Biotech AS
Pfizer Inc.
Pharmacyclics, Inc.
Pique Therapeutics
Piramal Enterprises Limited
PlantForm Corporation
PNP Therapeutics, Inc.
Profectus BioSciences, Inc.
Sareum Holdings plc
Selecta Biosciences, Inc.
SentoClone International AB
Serina Therapeutics, Inc.
Shionogi & Co., Ltd.
Silence Therapeutics plc
SillaJen Co. Ltd.
Synta Pharmaceuticals Corp.
Takara Bio Inc.
Teva Pharmaceutical Industries Limited
Theravectys S.A.
Transgene SA
VasGene Therapeutics, Inc.
VentiRx Pharmaceuticals, Inc.
Virttu Biologics Limited
Viventia Biotechnologies Inc.
VM Discovery, Inc.
Zhejiang BetaPharma Co., Ltd.
Zyngenia, Inc.

Complete report is available

Roger Campbell
United States
Ph: 888-789-6604